Stanley F. Chalvire

Representative Matters

• Represented Oscient Pharmaceuticals Corporation in its $78 million purchase of the U.S. rights to the cardiovascular drug Antara (fenofibrate) from Reliant Pharmaceuticals.
• Represented Oscient Pharmaceuticals Corporation in its acquisition of worldwide rights to Ramoplanin from Pfizer Inc. subsidiary Vicuron Pharmaceuticals Inc.
• Represented Agrivida, Inc. in its research alliance with Syngenta Ventures to develop advanced crop technology and provide Agrivida access to Syngenta crop technology and intellectual property.
• Represented ETEX Corporation in its sale to Zimmer Holdings, Inc.
• Represented Curadel, Inc. in its in-licensure of imaging technology from Beth Israel Deaconess Medical Center.
• Represented ProQR Therapeutics B.V. in its in-licensure of technology from Massachusetts General Hospital for the treatment of cystic fibrosis.
• Represented Virgin Pulse, Inc. in its in-licensure of trademarks from Virgin Enterprises Limited.
• Represented MacSpeech, Inc., a provider of speech recognition software, in its sale to Nuance Communications.
• Represented Outside The Classroom, Inc., a provider of the largest online alcohol prevention course AlcoholEdu®, in its sale to EverFi, Inc.